Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study

D Blockmans1, L De Ceuninck, S Vanderschueren

  • 1MD, PhD, Department of General Internal Medicine, University Hospital Leuven, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Daniel.Blockmans@uz.kuleuven.ac.be

Abstract

Insights

Fluorodeoxyglucose-positron emission tomography (FDG-PET) scans show vascular inflammation in only one-third of polymyalgia rheumatica (PMR) patients, and joint inflammation is common. FDG-PET results did not predict relapse risk in PMR.

Area of Science:

  • Nuclear Medicine
  • Rheumatology
  • Vascular Medicine

Background:

  • Polymyalgia rheumatica (PMR) is an inflammatory condition affecting large joints.
  • The role of vascular inflammation in PMR and its correlation with relapse risk requires further investigation.

Purpose of the Study:

  • To assess fluorodeoxyglucose (FDG) deposition in vascular beds and large joints of PMR patients.
  • To determine if FDG-positron emission tomography (PET) findings correlate with the risk of PMR relapse.

Main Methods:

  • Consecutive patients with isolated PMR underwent FDG-PET scans before steroid treatment.
  • Scans were evaluated for FDG uptake in seven vascular areas and large joints (shoulders, hips, vertebrae).
  • A total vascular score (TVS) was calculated, and joint uptake was graded.

Main Results:

  • Vascular FDG uptake was observed in 31% of patients at diagnosis, primarily in subclavian arteries.
  • FDG uptake was prevalent in shoulders (94%), hips (89%), and vertebral processi spinosi (51%).
  • Neither vascular nor joint FDG uptake intensity correlated with relapse risk.

Conclusions:

  • A minority of PMR patients exhibit significant vascular FDG uptake, mainly in the subclavian arteries.
  • The majority of PMR patients show joint inflammation on FDG-PET scans.
  • FDG-PET findings in PMR do not appear to predict the risk of disease relapse.